Oral Cromolyn Sodium
- Product Class: Polar Organic
- Indication: Treatment of asthma and allergy
- Status: Early Phase II patient testing in allergy patients confirms safety
- CY03 Next Steps: Determine the definitive efficacy for systemically delivered cromolyn in humans
- Product Profile: Cromolyn has an excellent safety profile; its clinical effectiveness as a locally delivered agent has been demonstrated in a wide variety of asthma and allergy indications
- High Margin Opportunity:
- Asthma affects an estimated 15 million Americans generating direct health care costs of $8.1 billion annually to the U.S.
- Allergy is also a multibillion U.S. market
- Both markets are currently underserved